Oxford BioMedica plc
https://www.oxb.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Oxford BioMedica plc
Asia Deal Watch: Ocumension Obtains Chinese Rights To Eight Alcon Products
Also deals involving WuXi/Medigene, Eisai/Seed, Genor/Two River/Third Rock Ventures, ImmuneOnco/Instil, Biocytogen/Ideaya, Takeda/Dr Reddy’s/Zydus/Mankind and deals in brief.
Korea Q2 Roundup: Hanmi Dispute Simmers, Emerging Obesity Focus
As it reported mixed second-quarter earnings, South Korea's pharma industry is increasingly turning to obesity pipeline assets. Meanwhile, leadership disputes among family members within Hanmi are resurfacing.
Can BIOSECURE Maintain Its Virality In The TikTok Era?
With the sheen of inevitability now scuffed off the BIOSECURE Act, diplomatic efforts to reduce US dependence on Chinese APIs are increasing in prominence. And the power of the legislation itself could be determined by litigation about a video app.
Chikungunya Vaccine, Hemophilia B Gene Therapy Among 14 Products On Track For EU Approval
The EU is on track to get its first vaccine for preventing the disease caused by chikungunya virus. Thirteen other products have also been recommended for pan-EU approval.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Oxxon Therapeutics Limited
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice